Man Reading Newspaper

News

Latest news regarding ScientificMed and our digital therapeutics.

Rectangle 178.png

Positive study results with a digital therapeutic (DTx) for breast cancer patients published in Supportive Care in Cancer


The pilot study "Patient interactive digital support for women with adjuvant endocrine therapy in order to increase compliance and quality of life" showed the app was perceived easy to use and of support in every-day life of breast cancer survivors. The patients especially appreciated the possibility to overview their reported symptoms over time in relation to their activities and physical exercise.

The primary aim of the study was to develop and investigate a patient interactive digital support (app) for patients on adjuvant endocrine breast cancer treatment. The project to develop the solution was a joint venture between the Capio St Görans hospital, ScientificMed, AstraZeneca and Novartis Sweden. It was supported with grants from the Region of Stockholm Innovation fund and with a sponsorship agreement from Novartis and AstraZeneca.

View Supportive Care in Cancer

For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00

Three Randomized Controlled Trials (RCTs), investigating the effects of a digital intervention (an app) to prevent childhood obesity are currently ongoing in Sweden, Spain and Rumania. The app is developed by researchers from two leading Swedish medical universities in collaboration with ScientificMed. The app is targeting parents to children at the age of 2-4 years, nudging them to good living habits with main focus on physical activity and nutrition. The app is available in Swedish, English, Spanish, Rumanian, Somali and Arabic and is currently in use in private and public health care. 

For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00

ScientificMed strengthens leadership with the addition of two new Board Members, Josefin Landgård and Martin Olovsson, and the Senior Business Advisor Annika Espander.

Press release.pdf


For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00.